Quest Diagnostics Incorporated (NYSE:DGX) Forecasted to Post FY2025 Earnings of $9.28 Per Share

Quest Diagnostics Incorporated (NYSE:DGX) – Equities research analysts at Zacks Research lifted their FY2025 earnings per share estimates for Quest Diagnostics in a research note issued on Thursday, May 16th. Zacks Research analyst M. Mondal now forecasts that the medical research company will post earnings of $9.28 per share for the year, up from their prior forecast of $9.27. The consensus estimate for Quest Diagnostics’ current full-year earnings is $8.78 per share. Zacks Research also issued estimates for Quest Diagnostics’ Q4 2025 earnings at $2.34 EPS.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.86 by $0.18. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The firm had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company posted $2.04 EPS. Quest Diagnostics’s revenue for the quarter was up 1.7% on a year-over-year basis.

A number of other equities analysts have also commented on DGX. SVB Leerink assumed coverage on shares of Quest Diagnostics in a report on Monday, February 26th. They issued a “market perform” rating and a $135.00 price objective on the stock. Jefferies Financial Group raised Quest Diagnostics from a “hold” rating to a “buy” rating and increased their price target for the company from $140.00 to $155.00 in a report on Wednesday, February 7th. StockNews.com downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. TheStreet cut Quest Diagnostics from a “b-” rating to a “c” rating in a research note on Monday, February 5th. Finally, Citigroup lifted their price target on shares of Quest Diagnostics from $135.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Ten equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $146.17.

Quest Diagnostics Stock Up 0.0 %

Shares of NYSE DGX traded up $0.07 during trading on Friday, reaching $142.50. 27,120 shares of the stock were exchanged, compared to its average volume of 1,024,637. The business’s 50-day moving average price is $132.36 and its 200 day moving average price is $132.52. The company has a market capitalization of $15.83 billion, a price-to-earnings ratio of 19.17, a price-to-earnings-growth ratio of 3.06 and a beta of 0.88. Quest Diagnostics has a twelve month low of $119.59 and a twelve month high of $145.58. The company has a quick ratio of 0.89, a current ratio of 0.97 and a debt-to-equity ratio of 0.59.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. NBC Securities Inc. acquired a new position in shares of Quest Diagnostics during the third quarter worth approximately $25,000. Altshuler Shaham Ltd bought a new position in shares of Quest Diagnostics in the fourth quarter worth $26,000. VisionPoint Advisory Group LLC grew its stake in shares of Quest Diagnostics by 100.0% in the third quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after purchasing an additional 109 shares in the last quarter. BKM Wealth Management LLC acquired a new position in shares of Quest Diagnostics during the fourth quarter valued at $29,000. Finally, Spartan Planning & Wealth Management acquired a new stake in Quest Diagnostics in the fourth quarter worth about $31,000. 88.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 661 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total value of $83,378.54. Following the transaction, the senior vice president now owns 40,206 shares of the company’s stock, valued at $5,071,584.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Michael E. Prevoznik sold 661 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $126.14, for a total transaction of $83,378.54. Following the completion of the transaction, the senior vice president now directly owns 40,206 shares in the company, valued at approximately $5,071,584.84. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Michael E. Prevoznik sold 5,611 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total value of $706,312.68. Following the completion of the sale, the senior vice president now owns 38,478 shares in the company, valued at $4,843,610.64. The disclosure for this sale can be found here. Insiders sold a total of 16,910 shares of company stock valued at $2,159,602 in the last quarter. Insiders own 0.79% of the company’s stock.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 22nd. Stockholders of record on Monday, July 8th will be issued a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 2.11%. The ex-dividend date is Monday, July 8th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 38.22%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.